Sept 3 (Reuters) – AbbVie said on Thursday its therapy for a type of blood cancer has met the main goals of a late-stage trial.
The therapy, etentamig, showed an overall response rate (ORR) of 74%, higher than the 45.7% recorded by standard treatments chosen by the trial investigator. ORR is the percentage of patients in a clinical trial whose cancer shrinks or disappears after treatment.
It also increased survival without progression of the disease, the other primary goal of the trial.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
